NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

Samankaltaisia teoksia

• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  Tekijä: Gow, Chien-Hung, et al.
  Julkaistu: (2005)
• Correction for Chiu et al., NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance
  Julkaistu: (2017)
• Higher nuclear EGFR expression is a better predictor of survival in rectal cancer patients following neoadjuvant chemoradiotherapy than cytoplasmic EGFR expression
  Tekijä: Yang, Ching-Chieh, et al.
  Julkaistu: (2019)
• Targeting ER Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to EGFR Inhibitors
  Tekijä: Wang, Yu-Chieh, et al.
  Julkaistu: (2008)
• The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
  Tekijä: Yang, Chih-Jen, et al.
  Julkaistu: (2017)